Document Detail


Clinical outcome and angiographic results with novel polysulfone polymer coating paclitaxel eluting stent in real-world clinical practice: a clinical centre registry.
MedLine Citation:
PMID:  20885360     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The Intek-Apollo stent (Switzerland) employs a polysulfone polymer coating which has demonstrated low interaction with blood and high thrombo-resistance. The aim of this study was to assess the clinical and angiographic outcomes after Intek-Apollo stent utilisation in a real-world setting.
MATERIAL/METHODS: A total of 130 patients (77.7% males) were enrolled with 174 lesions in native coronary arteries (92.4%), saphenous vein grafts (7.5%) and in-stent restenosis (6.3%). Indications for stenting were stable coronary artery disease (CAD) 52.3%, acute coronary syndrome (ACS) 37.7% and STEMI 10%. Clinical follow-up and coronary angiography (after symptoms occurrence or positive stress test) was performed at 6 and 12 months.The primary end points were target lesion revascularization (TLR) and target vessel revascularization (TVR), while secondary end points were major adverse cardiac events (MACE) during the follow-up period.
RESULTS: The mean age of patients included was 61.62±11.13 years. Complex lesions treatment (ostial, bifurcation) reached 13.7%. Mean stenosis diameter was 83.52±10.5%. Reference vessel diameter was 2.85±0.39 mm with a mean lesion length of 14.66±4.5mm. Average stent size was 2.93±0.39mm × 16.6±4.73 mm. At 15±3 months, primary events included TLR (4.6%), TVR (4.6%) and MACE (2.3%). There was 1one myocardial infarction and no cardiac death). No incidence of early or late stent thrombosis was demonstrated.
CONCLUSIONS: Intek-Apollo stent implantation is safe and efficient in a real world population. The unique properties of polysulfone polymer coating can effectively protect from late stent thrombosis and lead to reduced rates of TLR, TVR and MACE.
Authors:
Gerasimos Gavrielatos; Prodromos L Anthopoulos; Loukas K Pappas; Isidoros Gavaliatsis; Anastasios Salachas; Georgios Ifantis; Ioannis Antonelis
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Medical science monitor : international medical journal of experimental and clinical research     Volume:  16     ISSN:  1643-3750     ISO Abbreviation:  Med. Sci. Monit.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-04     Completed Date:  2011-04-18     Revised Date:  2011-06-14    
Medline Journal Info:
Nlm Unique ID:  9609063     Medline TA:  Med Sci Monit     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  MT77-82     Citation Subset:  IM    
Affiliation:
2nd Department of Cardiology, Evaggelismos General Hospital, Athens, Greece. makisgab@yahoo.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Coated Materials, Biocompatible / therapeutic use
Coronary Angiography / adverse effects
Coronary Artery Disease / complications,  radiography,  therapy
Coronary Disease / complications,  drug therapy,  radiography
Coronary Vessels / pathology
Drug-Eluting Stents*
Follow-Up Studies
Humans
Male
Middle Aged
Myocardial Infarction / complications,  epidemiology,  radiography
Paclitaxel / administration & dosage*,  therapeutic use
Polymers / therapeutic use
Registries
Sulfones / therapeutic use
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Coated Materials, Biocompatible; 0/Polymers; 0/Sulfones; 25135-51-7/polysulfone P 1700; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease the...
Next Document:  Prevalence and socio-behavioral determinants of dental caries in Sicilian schoolchildren.